MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jvir.2026.108001

Медицинская библиотека · Journal of vascular and interventional radiology : JVIR · 2026

Bronchial Arterial Chemoembolization Combined with Tislelizumab for Non-Small Cell Lung Cancer: An Exploratory, Prospective, Single-Arm, Phase II Trial.

Liang Chao, Han Daqian, Li Hao, Wang Manzhou, Kuang Donglin, Chen Huan, Miao Haolin, Chen Pengfei, Lu Huibin, Jiao Pengfei, Ren Jianzhuang, Han Xinwei, Li Fang, Duan Xuhua

СтатьяКлиническое исследование II фазыПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: To assess the effectiveness and safety of bronchial arterial chemoembolization (BACE) combined with tislelizumab for advanced non-small cell lung cancer (NSCLC).

MATERIALS AND

METHODS

In a prospective single-arm, Phase II study, patients with Stage IIIA-IIIC NSCLC who refused or were ineligible for standard treatments were enrolled. Patients received BACE followed by 200-mg tislelizumab every 3 weeks until disease progression, intolerable toxicities, or discontinuation determined by the investigators. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), safety, and quality of life (QoL).

RESULTS

Thirty patients (median age, 67 years, 24 men) were enrolled between December 2021 and August 2022. The median follow-up was 23 months (95% CI, 21.5-24.5). At data cutoff (March 1, 2024), median PFS was 10.5 months (95% CI, 7.8-13.2), and median OS was 15.0 months (95% CI, 8.2-21.8). ORR was 60.0% (18 of 30 patients), and DCR was 80.0% (24 of 30 patients). PD-L1 expression, tumor feeding arteries, and previous treatment history were prognostic factors for PFS and OS. Throughout the treatment and follow-up period, no Grade ≥3 treatment-related adverse events (TRAEs) were observed, as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Common Grade 1-2 TRAEs were nausea, chest pain, and anemia. QoL (global, physical, and emotional functioning) improved significantly after 1 treatment cycle versus baseline.

CONCLUSIONS

The prospective study suggests that BACE plus tislelizumab offer promising effectiveness and acceptable safety in advanced NSCLC, supporting further randomized trials.

Для цитирования: Liang Chao, Han Daqian, Li Hao, Wang Manzhou, Kuang Donglin, Chen Huan, Miao Haolin, Chen Pengfei, Lu Huibin, Jiao Pengfei, Ren Jianzhuang, Han Xinwei, Li Fang, Duan Xuhua. Bronchial Arterial Chemoembolization Combined with Tislelizumab for Non-Small Cell Lung Cancer: An Exploratory, Prospective, Single-Arm, Phase II Trial.. Journal of vascular and interventional radiology : JVIR. 2026. DOI: 10.1016/j.jvir.2026.108001.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.